Aurora Introduces Innovative Cannabis Oil Range to Meet Diverse Patient Needs in Australia

In This Article:

NASDAQ | TSX: ACB

Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch New Oil
Products for Enhanced Patient Care Options

EDMONTON, AB, Oct. 16, 2024 /CNW/ - Aurora Cannabis Inc., (NASDAQ: ACB) (TSX: ACB) – the Canadian based global leader in medical cannabis, in conjunction with MedReleaf Australia, is pleased to announce an enhanced product range of premium medical cannabis oil in Australia. This expansion reinforces Aurora's dedication to providing high-quality, innovative cannabis solutions to patients around the world. Now available for physicians to prescribe, the new cannabis oils include a variety of cannabinoid ratios to suit diverse patient needs.

Aurora Cannabis Inc. Logo (CNW Group/Aurora Cannabis Inc.)
Aurora Cannabis Inc. Logo (CNW Group/Aurora Cannabis Inc.)

The newly launched cannabis oil products include Aurora THC 25 (Sativa) in a 30mL bottle, Aurora THC 25 (Indica) in a 30mL bottle, Aurora 12.5:12.5 oil in a 30mL bottle, Aurora 50:50 oil in a 30mL bottle, and Aurora 10:100 oil in a 30mL bottle. Each formulation offers varying cannabinoid ratios to support personalized treatment options for patients.

"We are thrilled to bring this enhanced range of cannabis oil products to the Australian market," said Andre Jerome, Executive Vice President, Global Business Development at Aurora. "Our mission is to offer healthcare providers and their patients a broader selection of treatment options that meet their various medical needs. By expanding our product portfolio, we continue to demonstrate our commitment to advancing patient care through high-quality, science-driven cannabis solutions."

The newly available oils are developed and manufactured at Aurora's Canadian TGA and EU GMP certified facility, add to the expanding lineup with increased cannabinoid variety. The new products allow Doctors to tailor treatments more precisely, enhancing patient care. These offerings are another step forward in MedReleaf Australia's mission to expand access to quality medical cannabis options for patients across the country.

Key features of Aurora's new cannabis oil products include:

  • Comprehensive Cannabinoid Profiles: Designed to provide targeted and effective relief with a variety of THC and CBD ratios.

  • High Standards of Quality and Safety: Manufactured in TGA-GMP certified facilities, adhering to rigorous quality control measures.

  • Broad Selection: Wide range of unique oil formulations, allowing for customized patient care.

For additional information, healthcare professionals are encouraged to contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.